No Data
No Data
Annual Financial Report
FINANCIAL STATEMENTS
How long can the American customer love myth of high growth last? | Insight Research
Despite 3 consecutive years of high performance growth, market concerns about Aimeike's future growth momentum have not been resolved.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
Behind the slowdown in Aimeike's growth rate in the 3rd quarter: “Women's Maotai” can't handle the slump in consumption?
Demand weakens
“Ate” 19 hospitals in one go, and Aier Ophthalmology went to the county
Aier Ophthalmology is already a “veteran” of industrial fund mergers and acquisitions. On September 21, Aier Ophthalmology announced that it plans to spend 860 million yuan to acquire some shares in a total of 19 ophthalmology hospitals, including Hainan Air and Zaozhuang Aier, held by 6 industrial investment funds. According to statistics from TradeWind01 (ID: TradeWind01), the total revenue of these 19 hospitals in 2022 and January to July 2023 could reach 523 million yuan and 379 million yuan respectively. Judging from the geographical location of the merger and acquisition targets, a total of 6 ophthalmology hospitals including Hanchuan Aier are located in county-level cities, and a total of 3 ophthalmology hospitals including Yuanling Aier